| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$9.0M | ROE | −193.70% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $92.8M | Trading Days | 111 |
| 52W High | 48.91 |
| 52W Low | 1.91 |
| % Off High | −95.99% |
| Ann. Volatility (1Y) | 243.19% | Ann. Volatility (3Y) | 243.19% |
| Sharpe (1Y) | −1.51 | Sharpe (3Y) | −1.51 |
| Max Drawdown (1Y) | −94.40% | Max Drawdown (3Y) | −94.40% |
| YTD | −94.40% | Since inception | −94.40% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | $92.8M | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $92.0M | — |
| COYA | Coya Therapeutics, Inc. | $93.8M | — |
| ONCY | ONCOLYTICS BIOTECH INC | $94.5M | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.8M | — |
| BMEA | Biomea Fusion, Inc. | $90.4M | — |
| ALDX | Aldeyra Therapeutics, Inc. | $95.3M | — |
| RLYB | Rallybio Corp | $85.6M | — |
| GNPX | Genprex, Inc. | $85.0M | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $84.7M | — |
| TELO | Telomir Pharmaceuticals, Inc. |
| $84.6M |
| — |
| IXHL | Incannex Healthcare Inc. | $102.0M | — |
